UPCC 59425 Evaluating the Long-Term Outcomes of Relapsed or Refractory B-Cell Lymphoma Patients after CAR-T cell therapy

Enrolling By Invitation
99 years or below
All
Phase N/A
64 participants needed
1 Location

Brief description of study

This study aims to determine the long-term effects of CTL019 on patients who were enrolled in UPCC 13413: "Phase IIa Study of Redirected Autologous T-Cells Engineered to Contain Anti-CD 19 Attached to TCR and 4- BB Signaling Domains in Patients with Chemotherapy Relapsed of Refractory CD 19+ Lymphomas". It also aims to determine whether there are distinguishing molecular features for patients who achieved a long-term complete response to CTL019 therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 25-1642
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator